Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
LDL Cholesterol HELP
Based on 12,051 articles published since 2008
||||

These are the 12051 published articles about Cholesterol, LDL that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. 2018

Poli, Andrea / Barbagallo, Carlo M / Cicero, Arrigo F G / Corsini, Alberto / Manzato, Enzo / Trimarco, Bruno / Bernini, Franco / Visioli, Francesco / Bianchi, Alfio / Canzone, Giuseppe / Crescini, Claudio / de Kreutzenberg, Saula / Ferrara, Nicola / Gambacciani, Marco / Ghiselli, Andrea / Lubrano, Carla / Marelli, Giuseppe / Marrocco, Walter / Montemurro, Vincenzo / Parretti, Damiano / Pedretti, Roberto / Perticone, Francesco / Stella, Roberto / Marangoni, Franca. ·NFI - Nutrition Foundation of Italy, Italy. Electronic address: poli@nutrition-foundation.it. · Biomedical Department of Internal Medicine and Medical Specialistics (DIBIMIS), Università di Palermo, Italy. · Hypertension and Atherosclerosis Research Unit, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi Hospital, Università di Bologna and SINut - Italian Society of Nutraceuticals, Italy. · Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano and IRCCS MultiMedica, Milano, Italy. · Department of Medicine (DIMED), Geriatrics Division, Università di Padova and SISA - Italian Society for the Study of Atherosclerosis, Italy. · Department of Advanced Biomedical Sciences, Divisions of Cardiology and Cardiothoracic Surgery, Università Federico II di Napoli and SIPREC - Italian Society for Cardiovascular Prevention, Italy. · Department of Food and Drug, Università di Parma, Italy. · Department of Molecular Medicine, Università di Padova, Italy and IMDEA-Food, Madrid, Spain. · ARCA - Regional Association of Outpatient Cardiologists, Italy. · Obstetrics and Gynecology Unit, San Cimino Hospital, Termini Imerese and SIGO - Italian Society of Ginecology and Obstetrics, Italy. · AOGOI - Association of Italian Hospital Obstetricians and Gynecologists, Italy. · Department of Medicine-DIMED, Università di Padova and SID - Italian Society of Diabetology, Italy. · Department of Translational Medical Sciences, Università Federico II di Napoli and SIGG - Italian Society of Gerontology and Geriatrics, Italy. · Department of Obstetrics and Gynecology, Università di Pisa and SIM - Italian Menopause Society, Italy. · CREA - Alimenti e Nutrizione, Consiglio per la ricerca in agricoltura e l'analisi dell'economia agraria and SISA - Italian Society of Food Science and Nutrition, Italy. · Department of Experimental Medicine, Università la Sapienza di Roma and SIE - Italian Society of Endocrinology, Italy. · Endocrinology and Metabolic Diseases Unit, General Hospital, Vimercate and AMD - Italian Association of Diabetologists, Italy. · FIMMG, Italian Federation of General Medicine Doctors and SIMPeSV - Italian Society of Preventive and Lifestyle Medicine, Italy. · SIC - Italian Society of Cardiology, Italy. · SIMG - Italian College of General Practitioners and Primary Care Professionals, Italy. · Department of Medicine and Cardiac Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Pavia and GICR-IACPR - Italian Association for Cardiovascular Prevention and Rehabilitation, Italy. · Department of Medical and Surgical Sciences, Università Magna Graecia di Catanzaro and SIMI - Italian Society of Internal Medicine, Italy. · SNaMID - National Interdisciplinary Medical Society Primary Care, Italy. · NFI - Nutrition Foundation of Italy, Italy. ·Pharmacol Res · Pubmed #29859248.

ABSTRACT: Current evidence shows that cholesterol management either reduces the likelihood of cardiovascular disease (CVD) or slows down its progression. Hence, it is important that all health professionals make appropriate use of all the available intervention strategies to control risk factors: from dietary improvement and positive lifestyle changes to the use of functional foods, food supplements, and drugs. This review examines the effect of the most frequently occurring cholesterol-lowering substances in functional foods or in supplements across Europe, namely plant sterols and stanols, monacolin K found in red yeast rice, berberine and beta-glucans. We conclude that currently available supplements and functional foods can effectively reduce plasma LDL cholesterol levels by about 5 to 25%, either alone or in combination. Suitable candidates for these products are mainly individuals at low absolute cardiovascular risk at a young age or according to classic algorithms. Of note, despite being freely available for purchase, these products should be used following shared agreement between the physician and the patient ("concordance").

2 Guideline None 2017

Faludi, André Arpad / Izar, Maria Cristina de Oliveira / Saraiva, José Francisco Kerr / Bianco, Henrique Tria / Chacra, Ana Paula Marte / Bertoluci, Marcello Casaccia / Moreira, Rodrigo Oliveira / Turatti, Luiz Alberto Andreotti / Bertolami, Adriana / Sulzbach, Martha L / Schaan, Beatriz D / Valerio, Cynthia Melissa / Bertolami, Marcelo Chiara / Malachias, Marcus Vinícius Bolívar / Vencio, Sérgio / Betti, Roberto Tadeu Barcellos / Fonseca, Francisco Antonio Helfenstein / Salles, João Eduardo Nunes / Hohl, Alexandre. · ·Arq Bras Cardiol · Pubmed #29489927.

ABSTRACT: -- No abstract --

3 Guideline 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. 2017

Lloyd-Jones, Donald M / Morris, Pamela B / Ballantyne, Christie M / Birtcher, Kim K / Daly, David D / DePalma, Sondra M / Minissian, Margo B / Orringer, Carl E / Smith, Sidney C. · ·J Am Coll Cardiol · Pubmed #28886926.

ABSTRACT: In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non-statin therapies for low-density lipoprotein (LDL)-cholesterol lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk. Since the publication of that document, additional evidence and perspectives have emerged from randomized clinical trials and other sources, particularly considering the longer-term efficacy and safety of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in secondary prevention of ASCVD. Most notably, the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial and SPIRE-1 and -2 (Studies of PCSK9 Inhibition and the Reduction of Vascular Events), assessing evolocumab and bococizumab, respectively, have published final results of cardiovascular outcomes trials in patients with clinical ASCVD and in a smaller number of high-risk primary prevention patients. In addition, further evidence on the types of patients most likely to benefit from the use of ezetimibe in addition to statin therapy after acute coronary syndrome has been published. Based on results from these important analyses, the ECDP writing committee judged that it would be desirable to provide a focused update to help guide clinicians more clearly on decision making regarding the use of ezetimibe and PCSK9 inhibitors in patients with clinical ASCVD with or without comorbidities. In the following summary table, changes from the 2016 ECDP to the 2017 ECDP Focused Update are highlighted, and a brief rationale is provided. The content of the full document has been changed accordingly, with more extensive and detailed guidance regarding decision making provided both in the text and in the updated algorithms. Revised recommendations are provided for patients with clinical ASCVD with or without comorbidities on statin therapy for secondary prevention. The ECDP writing committee judged that these new data did not warrant changes to the decision pathways and algorithms regarding the use of ezetimibe or PCSK9 inhibitors in primary prevention patients with LDL-C <190 mg/dL with or without diabetes mellitus or patients without ASCVD and LDL-C ≥190 mg/dL not due to secondary causes. Based on feedback and further deliberation, the ECDP writing committee down-graded recommendations regarding bile acid sequestrant use, recommending bile acid sequestrants only as optional secondary agents for consideration in patients intolerant to ezetimibe. For clarification, the writing committee has also included new information on diagnostic categories of heterozygous and homozygous familial hypercholesterolemia, based on clinical criteria with and without genetic testing. Other changes to the original document were kept to a minimum to provide consistent guidance to clinicians, unless there was a compelling reason or new evidence, in which case justification is provided.

4 Guideline Consensus statement on the management of dyslipidaemias in adults. 2017

Anonymous13810893 / Anonymous13820893 / Anonymous13830893 / Béliard, S / Bonnet, F / Bouhanick, B / Bruckert, E / Cariou, B / Charrière, S / Durlach, V / Moulin, P / Valéro, R / Vergès, B. ·Service de nutrition, maladies métaboliques, endocrinologie, hôpital de la Conception, CHU de Marseille, AP-HM, 13009 Marseille, France. · Service d'endocrinologie-diabétologie, Inserm U1018, université Rennes 1, CHU de Rennes, Rennes, France. · Pôle CVM, service d'HTA et thérapeutique, CHU Rangueil, université de Toulouse 3, 331059 Toulouse, France. · Service d'endocrinologie, hôpital Pitié Salpêtrière, Paris, France. · Inserm UMR 1087, clinique d'endocrinologie, Institut du thorax, université de Nantes, CHU de Nantes, 44000 Nantes, France. · Fédération d'endocrinologie, GHE, HCL, université de Lyon 1, Inserm UMR 1060 CARMEN, 60003 Lyon, France. · Pôle thoracique cardiovasculaire et neurologique, hôpital Robert-Debré, 51092 Reims, France. · Fédération d'endocrinologie, GHE, HCL, université de Lyon 1, Inserm UMR 1060 CARMEN, 60003 Lyon, France. Electronic address: Philippe.moulin@chu-lyon.fr. · Pôle thoracique cardiovasculaire et neurologique, hôpital Robert-Debré, 51092 Reims, France; Service d'endocrinologie, diabétologie et maladies métaboliques, CHU de dijon, INSERM LNC UMR 866, Université Bourgogne Franche-Conté, 21000 Dijon, France. ·Ann Endocrinol (Paris) · Pubmed #28089403.

ABSTRACT: -- No abstract --

5 Guideline Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement. 2017

Anonymous10890893. · ·Am Fam Physician · Pubmed #28084711.

ABSTRACT: -- No abstract --

6 Guideline Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). 2017

Pirro, M / Vetrani, C / Bianchi, C / Mannarino, M R / Bernini, F / Rivellese, A A. ·Unit of Internal Medicine, Department of Medicine, University of Perugia, Perugia, Italy; Italian Society for the Study of Arteriosclerosis (SISA), Italy. · Department of Clinical Medicine and Surgery, "Federico II" University, Naples, Italy; Italian Society of Diabetology (SID), Italy. · Italian Society of Diabetology (SID), Italy; Unit of Diabetology and Metabolic Diseases, Department of Medical Area "Azienda Ospedaliero-Universitaria Pisana", Pisa, Italy. · Italian Society for the Study of Arteriosclerosis (SISA), Italy; Department of Pharmacy, University of Parma, Parma, Italy. · Department of Clinical Medicine and Surgery, "Federico II" University, Naples, Italy; Italian Society of Diabetology (SID), Italy. Electronic address: rivelles@unina.it. ·Nutr Metab Cardiovasc Dis · Pubmed #27956024.

ABSTRACT: AIM: Evidence showed that LDL-cholesterol lowering is associated with a significant cardiovascular risk reduction. The initial therapeutic approach to hypercholesterolemia includes dietary modifications but the compliance to recommendations is often inadequate. Some dietary components with potential cholesterol-lowering activity are present in small amounts in food. Therefore, in recent years the use of "nutraceuticals" (i.e., nutrients and/or bioactive compounds with potential beneficial effects on human health) has become widespread. Such substances may be added to foods and beverages, or taken as dietary supplements (liquid preparations, tablets, capsules). In the present manuscript, the cholesterol-lowering activity of some nutraceuticals (i.e. fiber, phytosterols, soy, policosanol, red yeast rice and berberine) will be discussed along with: 1) the level of evidence on the cholesterol-lowering efficacy emerging from clinical trial; 2) the possible side effects associated with their use; 3) the categories of patients who could benefit from their use. DATA SYNTHESIS: Based on the current literature, the cholesterol-lowering effect of fiber, phytosterols and red yeast rice is consistent and supported by a good level of evidence. Over berberine, there is sufficient evidence showing significant cholesterol-lowering effects, although the results come from studies carried out almost exclusively in Asian populations. Data on the effects of soy are conflicting and, therefore, the strength of recommendation is quite low. The evidence on policosanol is inconclusive. CONCLUSION: Although health benefits may arise from the use of nutraceuticals with cholesterol-lowering activity, their use might be also associated with possible risks and pitfalls, some of which are common to all nutraceuticals whereas others are related to specific nutraceuticals.

7 Guideline [ECS guidelines 2016 - dyslipidaemias]. 2016

Sinning, D / Landmesser, U. ·Klinik für Kardiologie, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Deutschland. · Klinik für Kardiologie, Charité - Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Deutschland. ulf.landmesser@charite.de. · Berlin Institute of Health (BIH), Berlin, Deutschland. ulf.landmesser@charite.de. · Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Berlin, Deutschland. ulf.landmesser@charite.de. ·Herz · Pubmed #27844136.

ABSTRACT: Dyslipidaemia is a major cause of atherosclerotic cardiovascular disease and its progression towards clinical complications, such as acute coronary syndromes and stroke. In August 2016 the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) issued new joint guidelines for the management of dyslipidaemias. In these new guidelines, the concept of treating patients to a risk-based low-density lipoprotein (LDL) cholesterol target is reinforced. The task force considers LDL cholesterol as the primary target for dyslipidaemia treatment, whereas high-density lipoprotein (HDL) cholesterol is not recommended as a treatment target (based on the failure of HDL cholesterol elevation treatment strategies to reduce cardiovascular risk in recent studies). In patients with a very high risk for cardiovascular events it is recommended to treat to an LDL cholesterol target of less than 70 mg/dl. Moreover, the new guidelines now additionally recommend a > 50% reduction of LDL cholesterol in patients with very high cardiovascular risk patients and baseline levels between 70 and 135 mg/dl as well as in patients with high cardiovascular risk and baseline LDL cholesterol levels between 100 and 200 mg/dl. Statins are recommended as first-line medicinal treatment and the LDL cholesterol goals given imply the more frequent use of maximum tolerated statin therapy, in particular for patients with very high cardiovascular risk. Treatment with ezetimibe in patients with substantially elevated LDL cholesterol levels despite maximum tolerated statin therapy has now received a stronger recommendation (currently IIa recommendation). The guidelines also now include the potential use of the novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and a recent ESC/EAS consensus document provides more detailed information on which patients can be considered for treatment with PCSK9 inhibitors, i. e. in particular patients with familial hypercholesterolemia and patients at very high cardiovascular risk who have markedly elevated LDL cholesterol levels despite maximum tolerated statin and ezetimibe therapy.

8 Guideline [ANMCO Position paper: Clinical management of hypercholesterolemia in patients with acute coronary syndrome]. 2016

Colivicchi, Furio / Gulizia, Michele Massimo / Arca, Marcello / Abrignani, Maurizio Giuseppe / Perna, Gian Piero / Mureddu, Gian Francesco / Nardi, Federico / Riccio, Carmine / Anonymous6540871. ·U.O.C. Cardiologia, Ospedale S. Filippo Neri, Roma. · U.O.C. Cardiologia, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi", Catania. · Centro Aterosclerosi, Policlinico Umberto I, Sapienza Università di Roma, Roma. · U.O.C. Cardiologia, Ospedale Civile Sant'Antonio Abate, Erice (TP). · U.O.C. Cardiologia, Azienda Ospedaliero-Universitaria "Ospedali Riuniti", Ancona. · U.O.C. Cardiologia, A.O. San Giovanni-Addolorata, Roma. · U.O.C. Cardiologia, Ospedale Castelli, Verbania. · U.O.C. Cardiologia e Riabilitazione Cardiologica, A.O. Sant'Anna e San Sebastiano, Caserta. ·G Ital Cardiol (Rome) · Pubmed #27311088.

ABSTRACT: LDL-cholesterol (LDL-C) reduction after acute coronary syndromes (ACS) is associated with a significant reduction in ischemic recurrences. Accordingly, international guidelines recommend a reduction of LDL-C below 70 mg/dl in ACS patients. Such a result can be accomplished by using high intensity statins, possibly associated with ezetimibe in selected cases. This document outlines the management strategies that can be consistently implemented in clinical practice in order to achieve and maintain guideline-recommended therapeutic goals.

9 Guideline [Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management. Differences Between the European and American Guidelines]. 2015

Lobos Bejarano, José María / Galve, Enrique / Royo-Bordonada, Miguel Ángel / Alegría Ezquerra, Eduardo / Armario, Pedro / Brotons Cuixart, Carlos / Camafort Babkowski, Miguel / Cordero Fort, Alberto / Maiques Galán, Antonio / Mantilla Morató, Teresa / Pérez Pérez, Antonio / Pedro-Botet, Juan / Villar Álvarez, Fernando / González-Juanatey, José Ramón / Anonymous4080836. ·Comité Español Interdisciplinario de Prevención Cardiovascular, España; Sociedad Española de Medicina de Familia y Comunitaria, Madrid, España. · Sección de Riesgo Vascular y Rehabilitación Cardiaca, Sociedad Española de Cardiología, Madrid, España. Electronic address: egalve@vhebron.net. · Comité Español Interdisciplinario de Prevención Cardiovascular, España; Instituto de Salud Carlos III, Madrid, España. · Sección de Riesgo Vascular y Rehabilitación Cardiaca, Sociedad Española de Cardiología, Madrid, España. · Comité Español Interdisciplinario de Prevención Cardiovascular, España; Sociedad Española de Hipertensión-Liga Española de la Lucha Contra la Hipertensión Arterial, Madrid, España. · Comité Español Interdisciplinario de Prevención Cardiovascular, España; Sociedad Española de Medicina Interna, Madrid, España. · Comité Español Interdisciplinario de Prevención Cardiovascular, España; Programa de Actividades Preventivas y de Promoción de la Salud (PAPPS), Madrid, España. · Sociedad Española de Medicina de Familia y Comunitaria, Madrid, España. · Comité Español Interdisciplinario de Prevención Cardiovascular, España; Sociedad Española de Diabetes, Madrid, España. · Sociedad Española de Arteriosclerosis, Madrid, España. · Comité Español Interdisciplinario de Prevención Cardiovascular, España; Sociedad Española de Arteriosclerosis, Madrid, España. · Sociedad Española de Cardiología, Madrid, España. ·Hipertens Riesgo Vasc · Pubmed #26179969.

ABSTRACT: The publication of the 2013 American College of Cardiology/American Heart Association guidelines on the treatment of high blood cholesterol has had a strong impact due to the paradigm shift in its recommendations. The Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology reviewed this guideline and compared it with current European guidelines on cardiovascular prevention and dyslipidemia management. The most striking aspect of the American guideline is the elimination of the low-density lipoprotein cholesterol treat-to-target strategy and the adoption of a risk reduction strategy in 4 major statin benefit groups. In patients with established cardiovascular disease, both guidelines recommend a similar therapeutic strategy (high-dose potent statins). However, in primary prevention, the application of the American guidelines would substantially increase the number of persons, particularly older people, receiving statin therapy. The elimination of the cholesterol treat-to-target strategy, so strongly rooted in the scientific community, could have a negative impact on clinical practice, create a certain amount of confusion and uncertainty among professionals, and decrease follow-up and patient adherence. Thus, this article reaffirms the recommendations of the European guidelines. Although both guidelines have positive aspects, doubt remains regarding the concerns outlined above. In addition to using risk charts based on the native population, the messages of the European guideline are more appropriate to the Spanish setting and avoid the possible risk of overtreatment with statins in primary prevention.

10 Guideline [ISRAELI GUIDELINES FOR THE TREATMENT OF HYPERLIPIDEMIA - 2014 UPDATE]. 2015

Bitzur, Rafael / Rozenman, Yoseph / Vinker, Shlomo / Dikerl, Dror / Shemesh, Joseph / Lahad, Amnon / Gavishl, Dov / Harats, Dror / KnobLer, Hilla / Anonymous1490836 / Anonymous1500836 / Anonymous1510836 / Anonymous1520836. · ·Harefuah · Pubmed #26168647.

ABSTRACT: Atherosclerosis is one of the leading causes of morbidity and mortality in the world, including in Israel. This document updates the clinical recommendations of the Israeli medical societies (The Society for Research, Prevention and Treatment of Atherosclerosis, The Israel Heart Society, The Israel Association of Family Physicians, The Israel Society of Internal Medicine) from 2012. The need for an update stems from new studies and from the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These recommendations take into account the guidelines of leading medical organizations in the world, as well as the specific circumstances and needs of the medical system in Israel.

11 Guideline Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology Position Statement on Dyslipidemia Management: differences between the European and American Guidelines. 2015

Lobos Bejarano, José María / Galve, Enrique / Royo-Bordonada, Miguel Ángel / Alegría Ezquerra, Eduardo / Armario, Pedro / Brotons Cuixart, Carlos / Camafort Babkowski, Miguel / Cordero Fort, Alberto / Maiques Galán, Antonio / Mantilla Morató, Teresa / Pérez Pérez, Antonio / Pedro-Botet, Juan / Villar Álvarez, Fernando / González-Juanatey, José Ramón / Anonymous2210829 / Anonymous2220829. · ·Rev Esp Salud Publica · Pubmed #25946582.

ABSTRACT: The publication of the 2013 American College of Cardiology/American Heart Association guidelines on the treatment of high blood cholesterol has had a strong impact due to the paradigm shift in its recommendations. The Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology reviewed this guideline and compared it with current European guidelines on cardiovascular prevention and dyslipidemia management. The most striking aspect of the American guideline is the elimination of the low-density lipoprotein cholesterol treat-to-target strategy and the adoption of a risk reduction strategy in 4 major statin benefit groups. In patients with established cardiovascular disease, both guidelines recommend a similar therapeutic strategy (high-dose potent statins). However, in primary prevention, the application of the American guidelines would substantially increase the number of persons, particularly older people, receiving statin therapy. The elimination of the cholesterol treat-to-target strategy, so strongly rooted in the scientific community, could have a negative impact on clinical practice, create a certain amount of confusion and uncertainty among professionals, and decrease follow-up and patient adherence. Thus, this article reaffirms the recommendations of the European guidelines. Although both guidelines have positive aspects, doubt remains regarding the concerns outlined above. In addition to using risk charts based on the native population, the messages of the European guideline are more appropriate to the Spanish setting and avoid the possible risk of overtreatment with statins in primary prevention.

12 Guideline [Homozygous familial hypercholesterolaemia: Spanish adaptation of the position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Consensus document of the Spanish Society of Arteriosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF)]. 2015

Ascaso, Juan F / Mata, Pedro / Arbona, Cristina / Civeira, Fernando / Valdivielso, Pedro / Masana, Luis. ·Sociedad Española de Arteriosclerosis. Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario de Valencia, INCLIVA, Universitat de València, Valencia, España. · Fundación Hipercolesterolemia Familiar, Madrid, España. · Unidad de Aféresis, Servicio de Hematología y Oncología, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, España. · Unidad Clínica y de Investigación en Lípidos y Arteriosclerosis, Servicio de Medicina Interna, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria de Aragón, Zaragoza, España. · Unidad de Lípidos, Servicio de Medicina Interna, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, España. · Unitat de Recerca de Lipids i Arteriosclerosi, Hospital Universitari Sant Joan, Universitat Rovira i Virgili, IISPV, Reus, Tarragona, España. Electronic address: luis.masana@urv.cat. ·Clin Investig Arterioscler · Pubmed #25757840.

ABSTRACT: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening disease characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). The Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) has recently published a clinical guide to diagnose and manage HoFH (Eur Heart J. 2014;35:2146-57). Both the Spanish Society of Atherosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF) consider this European Consensus document of great value and utility. However, there are particularities in our country which advise to have a Spanish adaptation of the European HoFH document in order to approximate this clinical guide to our environment. In Spain, chronic treatment with statins, ezetimibe and resins (colesevelam) has a reduced contribution in the National Health System (NHS) and is one of the few European countries where LDL apheresis is included in the Basic Service Portfolio coverage. This Spanish document also includes clinical experience in the management of these patients in our country. The Drafting Committee emphasizes the need for early identification of HoFH patients, prompt referral to specialized units, and an early and appropriate treatment. These recommendations will provide a guidance for HoFH patient management in Spain.

13 Guideline Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. 2015

Watts, Gerald F / Gidding, Samuel / Wierzbicki, Anthony S / Toth, Peter P / Alonso, Rodrigo / Brown, W Virgil / Bruckert, Eric / Defesche, Joep / Lin, Khoo Kah / Livingston, Michael / Mata, Pedro / Parhofer, Klaus G / Raal, Frederick J / Santos, Raul D / Sijbrands, Eric J G / Simpson, William G / Sullivan, David R / Susekov, Andrey V / Tomlinson, Brian / Wiegman, Albert / Yamashita, Shizuya / Kastelein, John J P / Anonymous3910792. ·Cardiometabolic Service, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia gerald.watts@uwa.edu.au. · Cardiology Division, Nemours Cardiac Nemours Cardiac Center, AI duPont Hospital for Children, Wilmington, and Jefferson Medical College, Philadelphia, USA. · Guy's and St Thomas' Hospitals, NHS Foundation Trust, London, UK. · CGH Medical Centre, Sterling, University of Illinois College of Medicine, Peoria, and Illinois Michigan State University College of Osteopathic Medicine, East Lansing, USA. · Lipid Clinic, Fundacion Jimenez Diaz, Madrid, Spain. · Emory University School of Medicine, Emory University, Atlanta, USA. · Hôpital Pitié-Salpêtrière, University of Paris VI, France. · Laboratory for Experimental Vascular Medicine, Section of Molecular Diagnostics, Academic Medical Centre, University of Amsterdam, The Netherlands. · Pontai Medical Centre, Heart Foundation of Malaysia, Kuala Lumpur, Malaysia. · The International FH Foundation, St Andrews Court, Thame, UK. · Fundacion Hipercolesterolemia Familiar, Madrid, Spain. · Division of Metabolism and Endocrinology, Ludwig-Maximilians-University of Munich, Germany. · Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. · Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School, University of Sao Paulo, Brazil. · Section of Pharmacology, Vascular and Metabolic Diseases, Erasmus Medical Centre, Erasmus University, Rotterdam, The Netherlands. · Aberdeen Royal Infirmary, University of Aberdeen, UK. · Lipid Clinic, Royal Prince Alfred Hospital, University of Sydney, Australia. · Laboratory of Clinical Lipidology, Ministry of Health of Russian Federation, Moscow, Russia. · Division of Clinical Pharmacology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, The People's Republic of China. · Academic Medical Centre, University of Amsterdam, The Netherlands. · Osaka University Graduate School of Medicine, Osaka University, Japan. ·Eur J Prev Cardiol · Pubmed #24776375.

ABSTRACT: Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL) cholesterol and causes premature coronary heart disease. There are at least 20 million people with FH worldwide, but the majority remains undetected and current treatment is often suboptimal.To address this major gap in coronary prevention we present, from an international perspective, consensus-based guidance on the care of FH. The guidance was generated from seminars and workshops held at an international symposium. The recommendations focus on the detection, diagnosis, assessment and management of FH in adults and children, and set guidelines for clinical purposes. They also refer to best practice for cascade screening and risk notifying and testing families for FH, including use of genetic testing. Guidance on treatment is based on risk stratification, management of non-cholesterol risk factors and safe and effective use of LDL lowering therapies. Recommendations are given on lipoprotein apheresis. The use of emerging therapies for FH is also foreshadowed.This international guidance acknowledges evidence gaps, but aims to make the best use of contemporary practice and technology to achieve the best outcomes for the care of FH. It should accordingly be employed to inform clinical judgment and be adjusted for country-specific and local healthcare needs and resources.

14 Guideline Cardiac risk factors: new cholesterol and blood pressure management guidelines. 2014

Anthony, David / George, Paul / Eaton, Charles B. ·Memorial Hospital of Rhode Island, 111 Brewster St., Pawtucket, RI 02903, USA. david_anthony@brown.edu · Warren Alpert Medical School of Brown University, 222 Richmond Street, Providence, RI 02903, USA. Paul-George@Brown.edu · Warren Alpert Medical School of Brown University, 222 Richmond Street, Providence, RI 02903, USA. Charles_Eaton@Brown.edu ·FP Essent · Pubmed #24936717.

ABSTRACT: The 2013 American College of Cardiology/American Heart Association cholesterol guidelines depart from low-density lipoprotein (LDL) treatment targets and recommend treating four specific patient groups with statins. Statins are the only cholesterol-lowering drugs with randomized trial evidence of benefit for preventing atherosclerotic cardiovascular disease (ASCVD). The groups are patients with clinical ASCVD; patients ages 40 to 75 years with diabetes and LDL of 70 to 189 mg/dL but no clinical ASCVD; patients 21 years or older with LDL levels of 190 mg/dL or higher; and patients ages 40 to 75 years with LDL of 70 to 189 mg/dL without clinical ASCVD or diabetes but with 10-year ASCVD risk of 7.5% or higher. Ten-year ASCVD risk may be calculated using the Pooled Cohort Equations. The Eighth Joint National Committee (JNC 8) guidelines for blood pressure management recommend a blood pressure goal of less than 140/90 mm Hg for all adults except those 60 years or older. For the latter group, the JNC 8 recommends a systolic blood pressure goal of less than 150 mm Hg. In another notable change from prior guidelines, the JNC 8 recommends relaxing the systolic blood pressure goal for patients with diabetes and chronic kidney disease to less than 140 mm Hg from less than 130 mm Hg.

15 Guideline [New thought from American new guideline on the treatment of blood cholesterol]. 2014

Zhao, Shuiping / Peng, Daoquan / Yu, Bilian / Huang, Xiansheng / Hu, Dayi / Shi, Xubo. · ·Zhonghua Xin Xue Guan Bing Za Zhi · Pubmed #24735622.

ABSTRACT: -- No abstract --

16 Guideline New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. 2014

Klose, Gerald / Beil, Frank Ulrich / Dieplinger, Hans / von Eckardstein, Arnold / Föger, Bernhard / Gouni-Berthold, Ioanna / Heigl, Franz / Koenig, Wolfgang / Kostner, Gert M / Landmesser, Ulf / Laufs, Ulrich / Leistikow, Frank / März, Winfried / Noll, Georg / Parhofer, Klaus G / Paulweber, Bernhard / Riesen, Walter F / Schaefer, Jürgen R / Steinhagen-Thiessen, Elisabeth / Steinmetz, Armin / Toplak, Hermann / Wanner, Christoph / Windler, Eberhard / Anonymous4800787. ·Practice for Internal Medicine, Gastroenterology, Cardiology and Preventive Medicine, Bremen, Germany. ·Wien Klin Wochenschr · Pubmed #24615676.

ABSTRACT: After the publication of the new guidelines of the European Society of Cardiology and the European Atherosclerosis Society for the prevention and treatment of dyslipidemias (Eur Heart J 32:1769-1818, 2011; Eur Heart J 33:1635-1701, 2012), a group of authors has recently published on behalf of the American Heart Association and the American College of Cardiology guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk (Circulation 2013). These new guidelines are supposed to replace the until now widely accepted, at least in the USA, recommendations of the National Cholesterol Education Program Adult Treatment Panel III from the years 2002 (Circulation 106:3143-3421, 2002) and 2004 (Circulation 110:227-39, 2004). Furthermore, they claim to be based mainly on hard evidence derived from the interpretation of results of prospective randomized controlled trials. This Joint Position Statement of the Society for the Prevention of Cardiovascular Diseases e.V. (D.A.CH), the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society of Cardiology concludes that the use of individualized prevention strategies based on specific indications and LDL cholesterol target concentrations, a strategy whose worth has been widely proven and accepted for more than a decade in Europe, should not be given up.

17 Guideline Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. 2014

Stone, Neil J / Robinson, Jennifer G / Lichtenstein, Alice H / Goff, David C / Lloyd-Jones, Donald M / Smith, Sidney C / Blum, Conrad / Schwartz, J Sanford / Anonymous1570783. · ·Ann Intern Med · Pubmed #24474185.

ABSTRACT: DESCRIPTION: In November 2013, the American College of Cardiology and American Heart Association (ACC/AHA) released a clinical practice guideline on the treatment of blood cholesterol to reduce cardiovascular risk in adults. This synopsis summarizes the major recommendations. METHODS: In 2008, the National Heart, Lung, and Blood Institute convened the Adult Treatment Panel (ATP) IV to update the 2001 ATP-III cholesterol guidelines using a rigorous process to systematically review randomized, controlled trials (RCTs) and meta-analyses of RCTs that examined cardiovascular outcomes. The panel commissioned independent systematic evidence reviews on low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol goals in secondary and primary prevention and the effect of lipid drugs on atherosclerotic cardiovascular disease events and adverse effects. In September 2013, the panel's draft recommendations were transitioned to the ACC/AHA. RECOMMENDATIONS: This synopsis summarizes key features of the guidelines in 8 areas: lifestyle, groups shown to benefit from statins, statin safety, decision making, estimation of cardiovascular disease risk, intensity of statin therapy, treatment targets, and monitoring of statin therapy.

18 Guideline Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. 2014

Tonelli, Marcello / Wanner, Christoph / Anonymous2770778. · ·Ann Intern Med · Pubmed #24323134.

ABSTRACT: DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2013 on lipid management and treatment of all adults and children with chronic kidney disease (CKD). All forms of CKD are included (non-dialysis-dependent, dialysis-dependent, and kidney transplant recipients). METHODS: The KDIGO Lipid Guideline Development Work Group defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence that had been summarized by an evidence review team. Searches of the English-language literature were conducted through August 2011 and supplemented by targeted searches through June 2013. Final modification of the guidelines was informed by the KDIGO Board of Directors and a public review process involving registered stakeholders. RECOMMENDATIONS: The full guideline includes 13 recommendations; a key element was the recommendation for statin or statin with ezetimibe treatment of adults aged 50 years or older with estimated glomerular filtration rates less than 60 mL/min/1.73 m2 but not treated with long-term dialysis or kidney transplantation. This synopsis focuses on 8 recommendations pertinent to assessment of lipid status and treatment with a statin-based regimen in adults.

19 Guideline 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014

Stone, Neil J / Robinson, Jennifer G / Lichtenstein, Alice H / Bairey Merz, C Noel / Blum, Conrad B / Eckel, Robert H / Goldberg, Anne C / Gordon, David / Levy, Daniel / Lloyd-Jones, Donald M / McBride, Patrick / Schwartz, J Sanford / Shero, Susan T / Smith, Sidney C / Watson, Karol / Wilson, Peter W F / Anonymous5090775. · ·J Am Coll Cardiol · Pubmed #24239923.

ABSTRACT: -- No abstract --

20 Guideline Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. 2013

Anonymous3250749 / Cole, Thomas G / Contois, John H / Csako, Gyorgy / McConnell, Joseph P / Remaley, Alan T / Devaraj, Sridevi / Hoefner, Daniel M / Mallory, Tonya / Sethi, Amar A / Warnick, G Russell. ·Thom Cole Consulting, LLC, St. Louis, MO 63122, USA. tgchol@aol.com ·Clin Chem · Pubmed #23386699.

ABSTRACT: BACKGROUND: The number of circulating LDL particles is a strong indicator of future cardiovascular disease (CVD) events, even superior to the concentration of LDL cholesterol. Atherogenic (primarily LDL) particle number is typically determined either directly by the serum concentration of apolipoprotein B (apo B) or indirectly by nuclear magnetic resonance (NMR) spectroscopy of serum to obtain NMR-derived LDL particle number (LDL-P). CONTENT: To assess the comparability of apo B and LDL-P, we reviewed 25 clinical studies containing 85 outcomes for which both biomarkers were determined. In 21 of 25 (84.0%) studies, both apo B and LDL-P were significant for at least 1 outcome. Neither was significant for any outcome in only 1 study (4.0%). In 50 of 85 comparisons (58.8%), both apo B and LDL-P had statistically significant associations with the clinical outcome, whereas in 17 comparisons (20.0%) neither was significantly associated with the outcome. In 18 comparisons (21.1%) there was discordance between apo B and LDL-P. CONCLUSIONS: In most studies, both apo B and LDL-P were comparable in association with clinical outcomes. The biomarkers were nearly equivalent in their ability to assess risk for CVD and both have consistently been shown to be stronger risk factors than LDL-C. We support the adoption of apo B and/or LDL-P as indicators of atherogenic particle numbers into CVD risk screening and treatment guidelines. Currently, in the opinion of this Working Group on Best Practices, apo B appears to be the preferable biomarker for guideline adoption because of its availability, scalability, standardization, and relatively low cost.

21 Guideline [Management of familial heterozygous hypercholesterolaemia. Position paper of the Polish Lipid Expert Forum]. 2013

Rynkiewicz, Andrzej / Cybulska, Barbara / Banach, Maciej / Filipiak, Krzysztof J / Guzik, Tomasz / Idzior Waluś, Barbara / Imiela, Jacek / Jankowski, Piotr / Kłosiewicz Latoszek, Longina / Limon, Janusz / Myśliwiec, Małgorzata / Opolski, Grzegorz / Steciwko, Andrzej / Stępińska, Janina / Zdrojewski, Tomasz / Anonymous2310748. ·I Katedra i Klinika Kardiologii, Gdański Uniwersytet Medyczny, Gdańsk. ·Kardiol Pol · Pubmed #23348551.

ABSTRACT: -- No abstract --

22 Guideline 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 2012

Fihn, Stephan D / Gardin, Julius M / Abrams, Jonathan / Berra, Kathleen / Blankenship, James C / Dallas, Apostolos P / Douglas, Pamela S / Foody, Joanne M / Gerber, Thomas C / Hinderliter, Alan L / King, Spencer B / Kligfield, Paul D / Krumholz, Harlan M / Kwong, Raymond Y K / Lim, Michael J / Linderbaum, Jane A / Mack, Michael J / Munger, Mark A / Prager, Richard L / Sabik, Joseph F / Shaw, Leslee J / Sikkema, Joanna D / Smith, Craig R / Smith, Sidney C / Spertus, John A / Williams, Sankey V / Anonymous1420743 / Anonymous1430743 / Anonymous1440743 / Anonymous1450743 / Anonymous1460743 / Anonymous1470743 / Anonymous1480743. · ·J Am Coll Cardiol · Pubmed #23182125.

ABSTRACT: -- No abstract --

23 Guideline [New European guidelines for the management of dyslipidaemia in cardiovascular prevention]. 2012

Descamps, O S / De Backer, G / Annemans, L / Muls, E / Scheen, A J / Anonymous4680726 / Anonymous4690726. ·Centre de Recherche Médicale de Jolimont et Département de Médecine Interne, Hôpital de Jolimont, Haine-Saint-Paul. olivierdescamps@hotmail.com ·Rev Med Liege · Pubmed #22611827.

ABSTRACT: The new guidelines from the European Atherosclerosis Society and the European Society of Cardiology include a number of updated items. In this paper, we summarize 4 of these changes that we consider to be the most pertinent. Firstly, cardiovascular risk is now stratified according to 4 (previously 2) categories: "very high risk" (patients with cardiovascular disease, patients with diabetes > 40 years old who have at least one other risk factor, patients with kidney failure, or patients in primary prevention with a SCORE value > or = 10%); "high risk" (patients in primary prevention with a SCORE value > or = 5% and < 10% or patients with a particularly serious risk factor such as familial hypercholesterolaemia or patients with diabetes < 40 years old without any other risk factor); "moderate risk" (primary prevention with SCORE > or = 1% and < 5%); and "low risk" (primary prevention with SCORE < 1%). The SCORE value for patients in primary prevention is estimated using the SCORE table (calibrated for Belgium). Risk in this table may now be corrected according to HDL cholesterol level. Secondly, the therapeutic targets for each category are now more stringent: LDL cholesterol < 70 mg/dl (or reduced by at least 50%) if the risk is "very high"; < 100 mg/dl if the risk is "high"; and < 115 mg/dl if the risk is "moderate". Thirdly, for patients at "high" or "very high" risk, particularly in patients with combined dyslipidaemia, two further therapeutic targets should be considered: non-HDL cholesterol and apolipoprotein B levels. Fourthly, the follow-up of efficacy (lipid profile) and tolerance (hepatic and muscular enzymes) is described in more details so as to harmonize case management in clinical practice.

24 Guideline South African dyslipidaemia guideline consensus statement. 2012

Klug, Eric / Anonymous4340719 / Anonymous4350719. ·eklug@global.co.za ·S Afr Med J · Pubmed #22380916.

ABSTRACT: The European Society of Cardiology together with the European Atherosclerosis Society published updated dyslipidaemia guidelines in 2011. SA Heart and the Lipid and Atherosclerosis Society of Southern Africa officially adopt these guidelines. This statement adapts aspects of the guidelines to the South African situation. Using the updated Framingham risk charts, interventional strategies are based according to the cardiovascular risk score and low-density lipoprotein cholesterol (LDL-C) levels. The Framingham risk score refers to the 10-year risk of any cardiovascular event, and includes four categories of risk. Treatment targets are those of the European guidelines. The LDL-C goal is 1.8 mmol/l for the very high-risk group (>30%), 2.5 mmol/l for the high-risk group (15-30%), and 3 mmol/l for those below 15% risk. Intensive management of dyslipidaemia in South Africa will significantly reduce the cardiovascular disease health burden.

25 Guideline Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. 2011

Daniels, Stephen R / Gidding, Samuel S / de Ferranti, Sarah D / Anonymous2460695. ·Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA. Daniels.Stephen@tchden.org ·J Clin Lipidol · Pubmed #21600527.

ABSTRACT: -- No abstract --

Next